{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T14:55:21Z","timestamp":1711637721469},"reference-count":18,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1586\/eci.11.15","type":"journal-article","created":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T19:00:40Z","timestamp":1305918040000},"page":"295-300","source":"Crossref","is-referenced-by-count":6,"title":["Ofatumumab in the treatment of low-grade non-Hodgkin\u2019s lymphomas and chronic lymphocytic leukemia"],"prefix":"10.1586","volume":"7","author":[{"given":"Celeste","family":"Bello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marays","family":"Veliz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"CIT0005","first-page":"949","volume":"101","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","volume":"28","author":"Wierda","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"Byrd","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Wierda W, Kipps T, D\u00fcrig Jet al.Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial.Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5\u20138 December 2009 (Abstract 207).","DOI":"10.1182\/blood.V114.22.207.207"},{"key":"CIT0012","unstructured":"Keating M, O\u2019Brien S, Lerner Set al.Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL).Program and Abstracts of the 2004 ASCO Annual Meeting. New Orleans, LA, USA, 5\u20138 June 2004."},{"key":"CIT0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.29.9792","volume":"28","author":"Parikh","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"CIT0015","doi-asserted-by":"crossref","unstructured":"Fischer K, Cramer P, Stilgenbauer Set al.Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter Phase II trial of the German CLL study group (GCLLSG).Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5\u20138 December 2009 (Abstract 205).","DOI":"10.1182\/blood.V114.22.205.205"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Hagenbeek A, Fayad L, Delwail Vet al.Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma.Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5\u20138 December 2009 (Abstract 935).","DOI":"10.1182\/blood.V114.22.935.935"},{"key":"CIT0018","doi-asserted-by":"crossref","unstructured":"Rummel M, Niederle N, Maschmeyer Get al.Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany).Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5\u20138 December 2009 (Abstract 405).","DOI":"10.1182\/blood.V114.22.405.405"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/eci.11.15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T10:57:14Z","timestamp":1592564234000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/eci.11.15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1586\/eci.11.15"],"URL":"https:\/\/doi.org\/10.1586\/eci.11.15","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}